Neoadjuvant interferon-based chemoradiation for borderline resectable and locally advanced pancreas cancer: A Phase II pilot study

Eric H Jensen, Leonard Armstrong, Chung K Lee, Todd M Tuttle, Selwyn M. Vickers, Timothy Sielaff, Edward W Greeno

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: Neoadjuvant chemoradiotherapy (CRT) is a viable treatment strategy for patients with pancreatic cancer. This study was conducted to evaluate the Virginia Mason Protocol (5-fluorouracil, cisplatin, interferon-α and radiation) given in the neoadjuvant setting for the treatment of locally advanced pancreatic cancer. Methods: A Phase II pilot study evaluating interferon-based neoadjuvant CRT in patients with locally advanced pancreatic cancer was performed. Results: A total of 23 patients were enrolled. The mean age of the patients was 58.6 years. Of the 23 patients, seven (30.4%) completed all treatments. In the remaining 16 (69.6%) patients, treatment was interrupted as a result of toxicity. The most commonly reported effects of toxicity were leucopoenia/cytopoenia (n = 19, 82.6%) and gastrointestinal effects (n = 19, 82.6%). Surgical resection was successful in seven (30.4%) patients. Margins were negative in six (85.7%) of these seven patients. Positive lymph nodes were identified in three (42.9%) of seven patients. Overall survival was 11.5 months. Surgery provided improved survival (22.6 months) compared with CRT alone (8.8 months). Disease-free survival in resected patients was 17.2 months. Conclusions: Interferon-based neoadjuvant CRT may allow for resection of locally advanced pancreatic cancer, but with significant toxicity. In the absence of surgical resection, survival remains dismal.

Original languageEnglish (US)
Pages (from-to)131-139
Number of pages9
JournalHPB
Volume16
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Pancreatic Neoplasms
Interferons
Chemoradiotherapy
Survival
Neoadjuvant Therapy
Fluorouracil
Cisplatin
Disease-Free Survival
Therapeutics
Lymph Nodes
Radiation

Cite this

Neoadjuvant interferon-based chemoradiation for borderline resectable and locally advanced pancreas cancer : A Phase II pilot study. / Jensen, Eric H; Armstrong, Leonard; Lee, Chung K; Tuttle, Todd M; Vickers, Selwyn M.; Sielaff, Timothy; Greeno, Edward W.

In: HPB, Vol. 16, No. 2, 02.2014, p. 131-139.

Research output: Contribution to journalArticle

Jensen, Eric H ; Armstrong, Leonard ; Lee, Chung K ; Tuttle, Todd M ; Vickers, Selwyn M. ; Sielaff, Timothy ; Greeno, Edward W. / Neoadjuvant interferon-based chemoradiation for borderline resectable and locally advanced pancreas cancer : A Phase II pilot study. In: HPB. 2014 ; Vol. 16, No. 2. pp. 131-139.
@article{6fd94fc7936a4a088bd8eafd63e4a0e8,
title = "Neoadjuvant interferon-based chemoradiation for borderline resectable and locally advanced pancreas cancer: A Phase II pilot study",
abstract = "Objectives: Neoadjuvant chemoradiotherapy (CRT) is a viable treatment strategy for patients with pancreatic cancer. This study was conducted to evaluate the Virginia Mason Protocol (5-fluorouracil, cisplatin, interferon-α and radiation) given in the neoadjuvant setting for the treatment of locally advanced pancreatic cancer. Methods: A Phase II pilot study evaluating interferon-based neoadjuvant CRT in patients with locally advanced pancreatic cancer was performed. Results: A total of 23 patients were enrolled. The mean age of the patients was 58.6 years. Of the 23 patients, seven (30.4{\%}) completed all treatments. In the remaining 16 (69.6{\%}) patients, treatment was interrupted as a result of toxicity. The most commonly reported effects of toxicity were leucopoenia/cytopoenia (n = 19, 82.6{\%}) and gastrointestinal effects (n = 19, 82.6{\%}). Surgical resection was successful in seven (30.4{\%}) patients. Margins were negative in six (85.7{\%}) of these seven patients. Positive lymph nodes were identified in three (42.9{\%}) of seven patients. Overall survival was 11.5 months. Surgery provided improved survival (22.6 months) compared with CRT alone (8.8 months). Disease-free survival in resected patients was 17.2 months. Conclusions: Interferon-based neoadjuvant CRT may allow for resection of locally advanced pancreatic cancer, but with significant toxicity. In the absence of surgical resection, survival remains dismal.",
author = "Jensen, {Eric H} and Leonard Armstrong and Lee, {Chung K} and Tuttle, {Todd M} and Vickers, {Selwyn M.} and Timothy Sielaff and Greeno, {Edward W}",
year = "2014",
month = "2",
doi = "10.1111/hpb.12086",
language = "English (US)",
volume = "16",
pages = "131--139",
journal = "HPB",
issn = "1365-182X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Neoadjuvant interferon-based chemoradiation for borderline resectable and locally advanced pancreas cancer

T2 - A Phase II pilot study

AU - Jensen, Eric H

AU - Armstrong, Leonard

AU - Lee, Chung K

AU - Tuttle, Todd M

AU - Vickers, Selwyn M.

AU - Sielaff, Timothy

AU - Greeno, Edward W

PY - 2014/2

Y1 - 2014/2

N2 - Objectives: Neoadjuvant chemoradiotherapy (CRT) is a viable treatment strategy for patients with pancreatic cancer. This study was conducted to evaluate the Virginia Mason Protocol (5-fluorouracil, cisplatin, interferon-α and radiation) given in the neoadjuvant setting for the treatment of locally advanced pancreatic cancer. Methods: A Phase II pilot study evaluating interferon-based neoadjuvant CRT in patients with locally advanced pancreatic cancer was performed. Results: A total of 23 patients were enrolled. The mean age of the patients was 58.6 years. Of the 23 patients, seven (30.4%) completed all treatments. In the remaining 16 (69.6%) patients, treatment was interrupted as a result of toxicity. The most commonly reported effects of toxicity were leucopoenia/cytopoenia (n = 19, 82.6%) and gastrointestinal effects (n = 19, 82.6%). Surgical resection was successful in seven (30.4%) patients. Margins were negative in six (85.7%) of these seven patients. Positive lymph nodes were identified in three (42.9%) of seven patients. Overall survival was 11.5 months. Surgery provided improved survival (22.6 months) compared with CRT alone (8.8 months). Disease-free survival in resected patients was 17.2 months. Conclusions: Interferon-based neoadjuvant CRT may allow for resection of locally advanced pancreatic cancer, but with significant toxicity. In the absence of surgical resection, survival remains dismal.

AB - Objectives: Neoadjuvant chemoradiotherapy (CRT) is a viable treatment strategy for patients with pancreatic cancer. This study was conducted to evaluate the Virginia Mason Protocol (5-fluorouracil, cisplatin, interferon-α and radiation) given in the neoadjuvant setting for the treatment of locally advanced pancreatic cancer. Methods: A Phase II pilot study evaluating interferon-based neoadjuvant CRT in patients with locally advanced pancreatic cancer was performed. Results: A total of 23 patients were enrolled. The mean age of the patients was 58.6 years. Of the 23 patients, seven (30.4%) completed all treatments. In the remaining 16 (69.6%) patients, treatment was interrupted as a result of toxicity. The most commonly reported effects of toxicity were leucopoenia/cytopoenia (n = 19, 82.6%) and gastrointestinal effects (n = 19, 82.6%). Surgical resection was successful in seven (30.4%) patients. Margins were negative in six (85.7%) of these seven patients. Positive lymph nodes were identified in three (42.9%) of seven patients. Overall survival was 11.5 months. Surgery provided improved survival (22.6 months) compared with CRT alone (8.8 months). Disease-free survival in resected patients was 17.2 months. Conclusions: Interferon-based neoadjuvant CRT may allow for resection of locally advanced pancreatic cancer, but with significant toxicity. In the absence of surgical resection, survival remains dismal.

UR - http://www.scopus.com/inward/record.url?scp=84892564999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892564999&partnerID=8YFLogxK

U2 - 10.1111/hpb.12086

DO - 10.1111/hpb.12086

M3 - Article

C2 - 23509924

AN - SCOPUS:84892564999

VL - 16

SP - 131

EP - 139

JO - HPB

JF - HPB

SN - 1365-182X

IS - 2

ER -